◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › T › TBPH

Theravance Biopharma Inc (TBPH) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-18

Theravance Biopharma Inc (TBPH) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 90 employees. Its market capitalization is roughly $884 million. In the fiscal year ended 2025-12-31, TBPH reported $107M in revenue and $106M in net income.

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.

Interactive charts & full statements → Open the TBPH valuation workbench →

TBPH Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$104M	$107M	$64M	$57M	$51M	$55M	$72M	$73M	$60M	$15M	$49M	$42M	$12M	$0M	$130M	$15M
Gross Profit	$93M	$102M	$27M	$17M	($12M)	($138M)	$72M	$73M	$60M	$9M	$46M	$37M	$8M	($120M)	$16M	$11M
Gross Margin %	89.4%	94.9%	41.5%	29.3%	-23.5%	-250.1%	100.0%	100.0%	98.8%	60.8%	94.0%	88.9%	65.3%	-53253.5%	12.4%	74.1%
Operating Income (EBIT)	$5M	($13M)	($47M)	($56M)	($92M)	($258M)	($298M)	($252M)	($239M)	($260M)	($180M)	($182M)	($233M)	($156M)	($10M)	($109M)
Operating Margin %	4.5%	-12.3%	-72.9%	-97.6%	-179.1%	-466.1%	-414.2%	-343.1%	-395.5%	-1690.7%	-371.0%	-431.8%	-1989.5%	-69152.2%	-7.4%	-736.1%
Net Income	$54M	$106M	($56M)	($55M)	$872M	($199M)	($278M)	($236M)	($216M)	($285M)	($191M)	($182M)	($237M)	($156M)	($10M)	($109M)
Net Margin %	51.6%	98.5%	-87.6%	-96.1%	1698.5%	-360.6%	-386.9%	-322.1%	-357.0%	-1855.0%	-391.9%	-432.6%	-2028.0%	-69152.2%	-7.4%	-736.1%
EBITDA	$68M	$137M	($38M)	($52M)	($76M)	($233M)	($288M)	($204M)	($212M)	($259M)	($176M)	($179M)	($230M)	($154M)	($6M)	($105M)
Earnings Per Share (EPS)	$1.01	$2.06	$-1.15	$-1.00	$11.85	$-2.87	$-4.46	$-4.25	$-3.99	$-5.45	$-4.26	$-5.34	$-7.46	$-4.84	$-0.30	$-3.43
Shares Outstanding (M)	52M	52M	49M	55M	74M	69M	62M	56M	54M	52M	45M	34M	32M	32M	32M	32M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TBPH Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$21M	$18M	$46M	$20M	$26M	$15M	$19M	$17M
Gross Profit	$19M	$18M	$44M	$12M	$16M	$4M	$9M	$8M
Gross Margin %	93.0%	100.0%	96.7%	59.4%	60.0%	25.6%	49.6%	45.1%
Operating Income (EBIT)	($1M)	($6M)	$18M	($6M)	($3M)	($14M)	($9M)	($11M)
Operating Margin %	-2.9%	-33.1%	38.3%	-32.3%	-10.4%	-93.8%	-49.1%	-64.2%
Net Income	($6M)	($5M)	$61M	$4M	$55M	($14M)	($16M)	($13M)
Net Margin %	-28.4%	-27.9%	133.0%	18.1%	209.3%	-88.2%	-82.8%	-75.3%
EBITDA	$1M	($6M)	$75M	($2M)	$74M	($13M)	($8M)	($9M)
Earnings Per Share (EPS)	$-0.11	$-0.10	$1.15	$0.07	$1.08	$-0.27	$-0.31	$-0.26
Shares Outstanding (M)	52M	51M	53M	52M	51M	50M	49M	49M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TBPH Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	$52M	$239M	($12M)	($27M)	($187M)	($208M)	($250M)	($238M)	($113M)	($201M)	($99M)	($169M)	($175M)	($121M)	($119M)	($83M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$2M	$1M	$3M	$7M	$3M	$7M	$2M	$2M	$3M	$3M	$3M	$3M	$4M
Free Cash Flow (FCF)	$52M	$238M	($12M)	($29M)	($188M)	($211M)	($257M)	($241M)	($120M)	($203M)	($101M)	($172M)	($178M)	($124M)	($122M)	($87M)
FCF Margin %	49.7%	221.9%	-18.4%	-51.3%	-365.3%	-382.0%	-357.7%	-328.8%	-199.0%	-1322.4%	-207.9%	-407.1%	-1525.2%	-54731.4%	-93.5%	-586.1%
Dividends Paid	—	—	—	—	$1M	—	$385M	—	—	$0M	$0M	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TBPH Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($9M)	$73M	($6M)	($7M)	$208M	$43M	($1M)	($5M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($9M)	$73M	($6M)	($7M)	$208M	$43M	($1M)	($5M)
FCF Margin %	-42.8%	414.0%	-13.2%	-32.6%	794.2%	279.7%	-5.8%	-30.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TBPH Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$470M	$486M	$354M	$382M	$607M	$375M	$469M	$409M	$560M	$441M	$639M	$300M	$338M	$25M	$21M	$14M
Cash & Cash Equivalents	$220M	$168M	$38M	$40M	$298M	$90M	$81M	$58M	$378M	$89M	$345M	$113M	$89M	$89M	—	—
Total Liabilities	$180M	$189M	$179M	$169M	$166M	$713M	$773M	$633M	$612M	$326M	$289M	$57M	$48M	$42M	$23M	$155M
Total Debt (Short + Long-Term)	$11M	$11M	$11M	$4M	$7M	$617M	$256M	$463M	$454M	$447M	$445M	$223M	$223M	$446M	$0M	$0M
Total Shareholders' Equity	$290M	$297M	$176M	$213M	$442M	($339M)	($304M)	($224M)	($52M)	$115M	$350M	$243M	$290M	($17M)	($7M)	($141M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TBPH viewer.

Other Companies in BIOTECHNOLOGY

LXRX · Lexicon Pharmaceuticals Inc — $912 million
HELP · Cybin Inc. Common Stock — $904 million
IMMX · Immix Biopharma Inc — $894 million
FTH · Faeth Therapeutics, Inc. — $891 million
ARDX · Ardelyx Inc — $883 million
RIGL · Rigel Pharmaceuticals Inc — $871 million
OLMA · Olema Pharmaceuticals Inc — $859 million
WVE · Wave Life Sciences Ltd — $857 million

← TBOTEK All “T” companies TBRG →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.